Viewing nowCombinationSevitension Tablets 5/40 mg
Olmesartan Medoxomil 40mg · Amlodipine Besylate 6.944mg
Tablet · Prescription medication · Combination
Dasan Pharmaceutical Co., Ltd.

MFDS item code 201500327 · Approved 2015.01.21 · Insurance code 678600330
Treatment of essential hypertension not controlled with monotherapy
Amlodipine or Olmesartan Medoxomil are medications used to treat essential hypertension. These medications are helpful in effectively lowering blood pressure when monotherapy does not sufficiently control blood pressure. If blood pressure is not properly managed, the risk of serious complications such as heart disease or stroke increases, making the use of these medications important for reducing risks and improving health. Amlodipine primarily lowers blood pressure by dilating blood vessels, while Olmesartan Medoxomil inhibits the action of angiotensin II, which causes an increase in blood pressure. These two medications are used effectively to control hypertension, either alone or in combination. Therefore, these medications improve blood pressure control in the treatment of essential hypertension.
Administer 1 tablet once daily with water, with or without food. If possible, it is recommended to take the drug at the same time each day (e.g., in the morning). Before administering this drug, it is recommended to adjust the dose using the individual components (amlodipine or olmesartan medoxomil). However, if blood pressure is not controlled with monotherapy using the individual components, switching directly to this drug may be considered. The maximum dose of this drug is 10/40 milligrams. The maximum blood pressure-lowering effect occurs within 2 weeks after administration; therefore, adjust the dose at intervals of 2 weeks or more, taking the patient's blood pressure response into consideration. The recommended doses are as follows. - 5/20 milligrams: For patients whose blood pressure is not adequately controlled with amlodipine 5 milligrams or olmesartan medoxomil 20 milligrams as monotherapy. - 10/20 milligrams: For patients whose blood pressure is not adequately controlled with olmesartan medoxomil 20 milligrams as monotherapy. - 5/40 milligrams: For patients whose blood pressure is not adequately controlled with 5/20 milligrams. - 10/40 milligrams: For patients whose blood pressure is not adequately controlled with 5/40 milligrams. ∘Patients with renal impairment: This drug has not been studied in patients with renal impairment. However, the maximum dose of olmesartan medoxomil in patients with mild to moderate renal impairment (creatine clearance 20-60mL/min) is 20 milligrams once daily. Use of this drug is not recommended in patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or in patients on dialysis. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. ∘Patients with reduced effective intravascular volume: For patients who may have reduced effective intravascular volume (e.g., patients receiving diuretics, particularly those with renal impairment), it is recommended to start treatment at a low dose while closely monitoring their condition. ∘Patients with hepatic impairment: Use with caution in patients with mild to moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil in patients with moderate hepatic impairment is 10 milligrams once daily, and the maximum dose is 20 milligrams once daily. In patients with hepatic impairment who are already receiving other antihypertensive drugs and/or diuretics, blood pressure and renal function should be closely monitored. This drug must not be administered to patients with severe hepatic impairment. (See section 2. Patients in whom this drug must not be administered, under Precautions for Use.) ∘Elderly patients: In general, initiate treatment at a low dose. When adjusting the dose, consider the patient's renal or cardiac function and comorbidities. In elderly patients, blood pressure should be monitored closely and more frequently.
∘Pediatric patients: The safety and efficacy of this drug have not been established in pediatric patients under 18 years of age.
This medication may cause serious harm to the fetus and newborn if taken during pregnancy in the second and third trimesters; therefore, it should be discontinued immediately upon confirmation of pregnancy. This medication should not be used in patients with known allergy to any of its components, severe liver impairment, aortic stenosis, biliary obstruction, those undergoing renal dialysis, in patients in shock, or certain diabetic patients. Patients with hypotension due to deficiency in fluid or sodium may experience hypotensive symptoms upon initial administration; thus, they should be carefully monitored and treated as needed if hypotension occurs. Due to the presence of components that dilate blood vessels, it should be administered with caution to patients with acute hypotension or cardiovascular diseases. Caution is required in patients with heart failure and renal function should be closely monitored in patients with impaired kidney function. The metabolism and elimination of this medication may be delayed in patients with impaired liver function, so dosage adjustments may be necessary. While taking this medication, adverse reactions such as dizziness, headache, hypotension, edema, dyspepsia, skin rash, etc. may occur, and if symptoms are severe, consultation with a doctor is advised. This medication may interact with other antihypertensive drugs, diuretics, potassium-sparing agents, etc., so if other medications are being taken, this must be disclosed. Women who are pregnant or planning to become pregnant should consult a doctor to explore safe alternative treatments, and caution is advised for breastfeeding women as this medication may affect the baby. This medication is not recommended for children under 18 years as safety and efficacy have not been established. Elderly patients should start with a low dose considering possible declines in liver, kidney, or heart function and accompanying diseases. In cases of overdose, severe hypotension and tachycardia may occur, requiring immediate medical treatment. This medication should be stored in a tightly sealed container, protected from moisture and heat, and kept out of reach of children.
Not everyone experiences these, and they can vary from person to person.
This medication must be stored in a tightly sealed container to prevent exposure to air and moisture. It is recommended to keep it at room temperature, between 1 and 30 degrees Celsius, avoiding excessive heat or cold.
Pale yellow round film-coated tablets
28 tablets (14 tablets/PTP x 2)
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationOlmesartan Medoxomil 40mg · Amlodipine Besylate 6.944mg
Tablet · Prescription medication · Combination
Dasan Pharmaceutical Co., Ltd.
CombinationOlmesartan Medoxomil 20mg · Amlodipine Besylate 6.944mg
Tablet · Prescription medication · Combination
Korea Daiichi Sankyo Co., Ltd.
CombinationOlmesartan Medoxomil 40mg · Amlodipine Besylate 6.944mg
Tablet · Prescription medication · Combination
Korea Daiichi Sankyo Co., Ltd.
CombinationOlmesartan Medoxomil 40mg · Amlodipine Besylate 13.888mg
Tablet · Prescription medication · Combination
Hanmi Daiichi Sankyo Co., Ltd.
Olmesartan Medoxomil · Amlodipine Besylate
Prescription medication · Combination
SYNEX Co., Ltd.
Olmesartan Medoxomil · Amlodipine Besylate
Prescription medication · Combination
Co., Ltd. Sainex
Olmesartan Medoxomil · Amlodipine Besylate
Prescription medication · Combination
SYNEX Co., Ltd.
CombinationAmlodipine Besylate 6.944mg · Olmesartan Medoxomil 40mg
Tablet · Prescription medication · Combination
Huons Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.